CLINICAL TRIALS
High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization
One-year results from the SCORE randomized trial
Eberhard Grube, MD, FACC*,*,
Alexandra Lansky, MD, FACC ,
Karl Eugen Hauptmann, MD ,
Carlo Di Mario, MD, FACC ,
Germano Di Sciascio, MD, FACC||,
Antonio Colombo, MD, FACC¶,
Sigmund Silber, MD, FACC#,
Juergen Stumpf, MD**,
Nicolaus Reifart, MD, FACC,
Jean Fajadet, MD,
Antonio Marzocchi, MD,
Joachim Schofer, MD||||,
Pierre Dumas, MD¶¶,
Rainer Hoffmann, MD##,
Giulio Guagliumi, MD***,
Mark Pitney, MD and
Mary E. Russell, MD, FACC
* Herzzentrum, Siegburg, Germany
Cardiovascular Research Foundation, New York, New York
Krandkenhaus Barmherzige Brueder, Trier, Germany
San Raffaele Hospital, Milan, Italy
|| University Campus Biomedico of Rome, Rome, Italy
¶ Columbus Hospital, Milan, Italy
# Cardiology Clinic, Munich, Germany
** Praxisklinik Kardiologie Angiologie Radiologie, Dresden, Germany
Main-Taunus Heart Institute, Bad Soden, Germany
Clinique Pasteur, Toulouse, France
Universita degli Studi Policlinico S. Orsola Istituto di Cardiologia, Bologna, Italy
|||| Center for Cardiology and Vascular Intervention, Hamburg, Germany
¶¶ Clinique du boise de Verriers, Antony, France
## Universitatsklinikum der RWTH Aachen, Aachen, Germany
*** Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
Prince of Wales Hospital, New South Wales, Australia
Boston Scientific Corporation, Natick, Massachusetts
Manuscript received March 8, 2004;
revised manuscript received April 8, 2004,
accepted June 14, 2004.
* Reprint requests and correspondence: Dr. Eberhard Grube, Herzzentrum, Ringstrasse 49, D-53721 Siegburg, Germany (Email: GrubeE{at}aol.com).
OBJECTIVES: The Study to COmpare REstenosis Rate between QueST and QuaDDS-QP2 (SCORE) trial was a multicenter, randomized, open-label trial comparing the safety and performance of 13- and 17-mm QuaDDS stents (n = 126) (Quanam Medical Corp., Santa Clara, California/Boston Scientific Corp., Natick, Massachusetts) versus uncoated control stents (n = 140) in focal, de novo coronary lesions.
BACKGROUND: The pioneering drug-delivery QuaDDS stent used four to six acrylate polymer sleeves, each loaded with 800 µg of the paclitaxel derivative 7-hexanoyltaxol.
METHODS: Clinical end points were assessed at 1, 6, and 12 months post procedure. Quantitative coronary angiography and intravascular ultrasound were performed post procedure and at six-month follow-up.
RESULTS: In the QuaDDS group, early stent thrombosis and myocardial infarction (MI) rates were significantly higher, leading to premature cessation of enrollment. For the QuaDDS group, the stent thrombosis rate increased from 3.2% to 10.3% between 1 and 12 months, associated with increased non–Q-wave MI and death rates. The angiographic restenosis rate at six months was reduced from 32.7% (control) to 7.4% (p < 0.0001). However, the primary end point was not met with six-month target vessel revascularization (TVR) rate as well as the composite major adverse cardiac event rates (cardiac death, MI, and TVR) comparable between groups.
CONCLUSIONS: Despite angiographic indications of potential anti-restenotic benefit, increased rates of stent thrombosis, MI, and cardiac death associated with the QuaDDS stent show an unacceptable safety profile.
|
Abbreviations and Acronyms
| | IVUS = intravascular ultrasound | | MACE = major adverse cardiac event | | MI = myocardial infarction | | QCA = quantitative coronary angiography | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Grube, K. D. Dawkins, G. Guagliumi, A. P. Banning, K. Zmudka, A. Colombo, L. Thuesen, K. Hauptman, J. Marco, W. Wijns, et al.
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions
Eur. Heart J.,
November 1, 2007;
28(21):
2578 - 2582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Stahli, G. G. Camici, J. Steffel, A. Akhmedov, K. Shojaati, M. Graber, T. F. Luscher, and F. C. Tanner
Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH2 Kinase Activation
Circ. Res.,
July 21, 2006;
99(2):
149 - 155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsimikas
Drug-Eluting Stents and Late Adverse Clinical Outcomes: Lessons Learned, Lessons Awaited
J. Am. Coll. Cardiol.,
May 16, 2006;
47(10):
2112 - 2115.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Roiron, P Sanchez, A Bouzamondo, P Lechat, and G Montalescot
Drug eluting stents: an updated meta-analysis of randomised controlled trials
Heart,
May 1, 2006;
92(5):
641 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wessely, A. Schomig, and A. Kastrati
Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different
J. Am. Coll. Cardiol.,
February 21, 2006;
47(4):
708 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jaschke, C. Michaelis, S. Milz, M. Vogeser, T. Mund, L. Hengst, A. Kastrati, A. Schomig, and R. Wessely
Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform
Cardiovasc Res,
December 1, 2005;
68(3):
483 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Nawarskas and L. A. Osborn
Paclitaxel-eluting stents in coronary artery disease
Am. J. Health Syst. Pharm.,
November 1, 2005;
62(21):
2241 - 2251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, E. J. Orav, S. C. Candia, D. E. Cutlip, and R. E. Kuntz
Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized Trials
Circulation,
November 1, 2005;
112(18):
2833 - 2839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T.L. Ong, E. P. McFadden, E. Regar, P. P.T. de Jaegere, R. T. van Domburg, and P. W. Serruys
Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents
J. Am. Coll. Cardiol.,
June 21, 2005;
45(12):
2088 - 2092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. O'Neill, S. R. Dixon, and C. L. Grines
The year in interventional cardiology
J. Am. Coll. Cardiol.,
April 5, 2005;
45(7):
1117 - 1134.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J.,
April 2, 2005;
26(8):
804 - 847.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
137 - 153.
[Full Text]
[PDF]
|
|
|
|
